Compositions and methods for the treatment of gastrointestinal polyps

Patent metadata

Field	Value
Publication number	US-11225464-B2
Application number	US-201716348954-A
Country	US
Kind code	B2
Filing date	Apr 19, 2017
Priority date	Nov 11, 2016
Publication date	Jan 18, 2022
Grant date	Jan 18, 2022

Abstract

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.

First claim

What is claimed is:

1. A compound of Formula I:

and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;
wherein
R 1 , R 3 , and R 5 each independently represents NULL,

R 2 , and R 4 each independently represents

n is independently 1, 2, 3, 4 or 5;
a is independently 2, 3 or 7;
each b is independently 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are each independently H, D, —OH, —OD, C 1 -C 6 -alkyl, —NH 2 or —COCH 3 ; and
wherein R 6 is represented by

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration.

4. The pharmaceutical composition of claim 3 formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation.

5. A method of treating at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease comprising: administering the compound of claim 1 to patient suffering from at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease, wherein said compound of claim 1 is selected from the group consisting of

6. A compound of claim 1 selected from the group consisting of

7. A pharmaceutical composition comprising a compound of claim 6 , and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 , which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration.

9. The pharmaceutical composition of claim 8 formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation.

Assignees

• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• C07C317/44

  having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton · CPC title

• C07D239/94 Primary

  Nitrogen atoms · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07C229/30

  the carbon skeleton being acyclic and unsaturated · CPC title